Nov 20, 2018 7:30am EST ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments
Nov 06, 2018 7:30am EST ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Oct 31, 2018 7:30am EDT ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
Oct 11, 2018 7:30am EDT ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Sep 17, 2018 7:30am EDT ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
Aug 21, 2018 7:30am EDT ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development